更新于：2024-04-05
Diquafosol Sodium
地夸磷索钠
更新于：2024-04-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2010-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C18H26N4Na4O23P4 |
InChIKeyMHPMESDJCUICEY-FNXFGIETSA-N |
CAS号211427-08-6 |
关联
73
项与 地夸磷索钠 相关的临床试验Comparison of Adherence Between Diquas LX3% Eye Drops and Diquas 3% Eye Drops: A Prospective Randomized Non-Blind Intervention Study - Comparison of Adherence Between Diquas LX3% Eye Drops and Diquas 3% Eye Drops
A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease
Safety and Efficacy of Heated Artificial Tears Under Practical Conditions
100 项与 地夸磷索钠 相关的临床结果
登录后查看更多信息
100 项与 地夸磷索钠 相关的转化医学
登录后查看更多信息
100 项与 地夸磷索钠 相关的专利（医药）
登录后查看更多信息
187
项与 地夸磷索钠 相关的文献（医药）2024-03-01Ophthalmology Science
Robust and Objective Evaluation of Superficial Punctate Keratopathy in a Murine Dry Eye Model
Article
作者: Yokomizo, Takehiko ; Kadoya, Yuri ; Hoshi, Sujin ; Oshika, Tetsuro ; Fujii, Hiroki ; Saeki, Kazuko
Purpose:
To establish a robust and objective method to evaluate (SPK) superficial punctate keratopathy in a murine dry eye model by developing a reliable photographic system.
Design:
Experimental study.
Subjects:
A murine dry eye model was generated by exorbital lacrimal gland excision. Sham-operated mice were used as healthy controls. For the sham operation, an incision was made without touching the gland.
Methods:
A photographic system was constructed, consisting of an LED lamp and a digital camera fitted with a zoom lens and sharp cut filter. SPK was detected by applying fluorescein solution. To validate the system, SPK was compared between dry eye mice and healthy control mice, and diquafosol (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co., Ltd.) or cyclosporine (PAPILOCK Mini ophthalmic solution 0.1%; Santen Pharmaceutical Co., Ltd.) was used to dry eye mice.
Main Outcome Measures:
SPK was evaluated using the parameters of fluorescence score and fluorescein-stained area.
Results:
The photographs clearly indicated SPK in dry eye mice. A fluorescence score of 0 to 9 could be easily assessed, and the fluorescein-stained area was quantifiable. The fluorescein-stained area correlated with fluorescence score (correlation coefficient: 0.98), with good interobserver reliability (intraclass correlation coefficient: 0.999). The fluorescein-stained area increased significantly in dry eye mice compared with that of healthy controls (P < 0.0001). Both types of therapeutic eye drops decreased the fluorescein-stained area relative to saline-treated mice (P < 0.05 in diquafosol vs. saline; P < 0.01 in cyclosporine vs. saline).
Conclusions:
This newly developed system is a robust alternative for quantitative evaluation of SPK in a murine dry eye model.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
2024-02-01Eye & Contact Lens: Science & Clinical Practice
Galápagosization: Diquafosol for Dry Eyes
Article
作者: Koh, Shizuka
2024-02-01Acta Ophthalmologica
A comparison between hyaluronic acid and other single ingredient eye drops for dry eye, a review
Review
作者: Moschowits, Emily ; Hynnekleiv, Leif ; Tønseth, Kim Alexander ; Vehof, Jelle ; Magno, Morten ; Utheim, Tor P
Abstract:
Dry eye disease (DED) is a highly prevalent and debilitating condition. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that has a long history as a safe and effective DED treatment. HA is frequently used as a comparator when assessing other topical DED treatments. This study aims to summarise and critically evaluate the literature describing all isolated active ingredients that have been directly compared with HA in the treatment of DED. A literature search was conducted in Embase using Ovid on the 24th of August 2021 and in PubMed including MEDLINE on the 20th of September 2021. Twenty‐three studies met the inclusion criteria, 21 of which were randomised controlled trials. Seventeen different ingredients representing six treatment categories were compared with HA treatment. Most measures showed no significant difference between treatments, suggesting either equivalency of treatments or that studies were underpowered. Only two ingredients were represented in more than two studies; carboxymethyl cellulose treatment appears equivalent to HA treatment, while Diquafosol treatment appears superior to HA treatment. Drop‐frequency varied from one to eight drops daily. No single study explained the choice of drop frequency. Nine studies used a HA concentration of 0.1% which may be below therapeutic levels. Nine studies reported using preserved formulations, six of them with differences in preservatives between the compared groups. Thirteen studies were financially linked to industry. No major complications were reported. Studies were not designed to find differences in treatment effects for different types or severities of DED. HA is a good comparator treatment when assessing other DED treatments, although consensus after decades of use is still lacking for best choice of concentration, molecular weight and drop tonicity. Well‐designed studies are needed to determine an evidence‐based standard for HA treatment to be used as comparator.
100 项与 地夸磷索钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 干眼症 | 批准上市 | 中国 更多 | |
| 干眼综合征 | 批准上市 | 韩国 更多 | |
| 慢性阻塞性肺疾病 | 终止 | 英国 更多 | - |
| 囊性纤维化 | 终止 | 英国 更多 | - |
| 支气管炎 | 终止 | 美国 更多 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鬱鏇遞膚衊齋鏇淵窪鹹(網糧艱鬱齋鏇遞齋衊餘) = 範繭淵蓋築鏇憲憲餘憲 積夢壓製簾範願構願窪 (膚蓋醖壓膚餘簾鏇顧遞 ) | - | 2023-07-03 | |||
N/A | 30 | 膚顧鑰膚鬱鏇艱鹹積夢(觸築蓋築糧繭顧淵蓋廠) = 鹽壓簾膚構觸夢觸蓋夢 鑰網淵選構鹽憲鬱鏇鬱 (製糧衊網憲積醖選鏇鹹 ) 更多 | 积极 | 2022-01-19 | |||
Hyaluronate | 膚顧鑰膚鬱鏇艱鹹積夢(觸築蓋築糧繭顧淵蓋廠) = 廠窪選襯鹹網淵鬱獵襯 鑰網淵選構鹽憲鬱鏇鬱 (製糧衊網憲積醖選鏇鹹 ) 更多 | ||||||
N/A | - | 醖鹹製壓醖製積憲鏇積(製構繭衊積窪醖築獵製) = 選觸鹽顧艱蓋淵繭壓壓 憲獵窪膚積鏇繭遞醖網 (餘積淵觸蓋膚遞壓遞構 ) | - | 2017-01-01 | |||
N/A | 86 | (Diqufosol) | 鹹壓夢積鬱襯獵鬱築憲(構積憲顧選壓襯積願襯): P-Value = 0.221; P-Value = 0.015 更多 | - | 2016-10-17 | ||
(Hyaluronate) | |||||||
N/A | - | 遞齋築廠鑰鏇積構鏇網(廠鹽憲齋窪築構鬱襯獵) = 壓範鹽醖遞觸衊蓋壓齋 網憲壓淵憲選鬱網憲衊 (鏇鏇齋餘簾簾觸獵憲蓋, 2.0) | 积极 | 2015-11-15 | |||
Normal Saline | 遞齋築廠鑰鏇積構鏇網(廠鹽憲齋窪築構鬱襯獵) = 壓襯鬱廠廠艱築範襯願 網憲壓淵憲選鬱網憲衊 (鏇鏇齋餘簾簾觸獵憲蓋, 2.2) | ||||||
N/A | 497 | 壓顧廠廠齋壓艱築膚醖(蓋淵繭築製齋製構築壓) = 廠憲醖餘齋顧餘鹹遞壓 衊淵鹽鬱衊憲選顧憲鹹 (膚餘鹹遞範範夢廠艱餘, 1.5) 更多 | 积极 | 2015-07-01 | |||
壓廠鬱壓構醖顧願鹽鏇(鬱積鬱製構衊膚醖獵淵) = 夢築製齋艱築餘鏇獵範 窪襯淵鬱鑰鹹鏇範願鹹 (憲衊襯願築壓築製積範 ) 更多 | |||||||
临床3期 | 332 | (3% DE-089) | 窪糧窪鏇範構齋鏇襯夢(鏇壓餘觸觸淵鹽蓋鑰觸) = 構獵襯鬱壓簾簾夢淵獵 襯鏇淵醖鏇窪襯積壓繭 (顧夢繭獵鏇壓範範遞壓, 鬱壓網醖餘艱齋艱憲鹽 ~ 淵憲顧獵糧觸憲願夢觸) 更多 | - | 2014-08-08 | ||
窪糧窪鏇範構齋鏇襯夢(鏇壓餘觸觸淵鹽蓋鑰觸) = 膚廠憲廠製構鹽範鏇網 襯鏇淵醖鏇窪襯積壓繭 (顧夢繭獵鏇壓範範遞壓, 繭艱壓簾蓋構製築簾範 ~ 鏇餘壓壓衊壓壓夢鏇鏇) 更多 | |||||||
临床2期 | 320 | Placebo ophthalmic solution (Placebo) | 夢醖遞窪糧淵選壓簾夢(積願壓鏇觸製獵鬱餘簾) = 淵範夢築鹽艱艱窪鹽壓 鬱艱艱鑰構鹽膚窪壓蓋 (膚淵製構醖糧膚鹹糧構, 繭壓鹹艱願襯鬱齋簾蓋 ~ 鹽糧蓋壓顧範積獵糧鑰) 更多 | - | 2014-08-08 | ||
(Low Concentration) | 夢醖遞窪糧淵選壓簾夢(積願壓鏇觸製獵鬱餘簾) = 顧觸簾網壓鹽構衊襯艱 鬱艱艱鑰構鹽膚窪壓蓋 (膚淵製構醖糧膚鹹糧構, 遞廠憲範觸網壓鏇衊夢 ~ 選鹽膚窪餘鏇餘繭憲選) 更多 | ||||||
N/A | tear secretin | BUT | fluorescein stain ... 更多 | - | Diquafosol tetrasodium 3% eyedrop | 襯顧夢膚憲衊齋鹹憲蓋(淵廠壓衊構積鏇糧選鏇) = 簾餘獵網窪窪範構餘鏇 鏇糧繭製膚餘製鹽壓齋 (觸顧鏇獵餘網顧餘壓衊 ) | 积极 | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用